Last reviewed · How we verify
The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization
Polycystic Ovary Syndrome is the most common endocrine disorder in women, is estimated to affect more than 5% of the population and is associated with chronically elevated serum androgen concentrations.Evidence suggests that polycystic ovary syndrome has a negative impact on pregnancy outcomes, with an increased risk of gestational diabetes, hypertensive disease during pregnancy,and preterm birth,which is partially related with the hyperandrogenic environment.Diane-35 has been proved to be the most effective anti-androgenic drug.At present, there is no direct evidence that Diane-35 has a positive effect on the clinical outcome of polycystic ovary syndrome patients undergoing In-vitro fertilization/Intracytoplasmic sperm injection.
Details
| Lead sponsor | First Affiliated Hospital, Sun Yat-Sen University |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 100 |
| Start date | 2012-12 |
| Completion | 2014-12 |
Conditions
- Polycystic Ovary Syndrome
Interventions
- Diane-35 pretreatment
- Diane-35 pretreatment
Primary outcomes
- fertilization rate — up to 2years
Countries
China